Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Hira Rizvi"'
Autor:
Diana Saravia, Andrew J. Plodkowski, Annapaola Mariniello, Benjamin Besse, Lizza E.L. Hendriks, Maria Lucia Reale, Fabrizio Tabbò, Gilberto Lopes, Lydie Cassard, Anne-Marie C. Dingemans, Kathryn C. Arbour, Matthew D. Hellmann, Margarita Majem, Hira Rizvi, Edouard Auclin, Jeffrey Girshman, Silvia Novello, M. Naigeon, Simona Carnio, Nathalie Cozic, F. Blanc-Durand, Laura Mezquita, Clarisse Audigier-Valette, Peter Sawan, Paolo Bironzo, Nathalie Chaput, Jose Carlos Ruffinelli, Luis Paz-Ares, Patricia Martin-Romano, Ernest Nadal, Melinda Charrier, Wungki Park, Isabel Ruth Preeshagul, David Planchard, Santiago Ponce, Gérard Zalcman, Caroline Rossoni
Publikováno v:
EUROPEAN JOURNAL OF CANCER
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Instituto de Salud Carlos III (ISCIII)
European Journal of Cancer, 151, 211-220. ELSEVIER SCI LTD
European Journal of Cancer, 151, 211-220. Elsevier Ltd.
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Instituto de Salud Carlos III (ISCIII)
European Journal of Cancer, 151, 211-220. ELSEVIER SCI LTD
European Journal of Cancer, 151, 211-220. Elsevier Ltd.
Background: dNLR at the baseline (B), defined by neutrophils/[leucocytes-neutrophils], correlates with immune-checkpoint inhibitor (ICI) outcomes in advanced non-small-cell lung cancer (aNSCLC). However, dNLR is dynamic under therapy and its longitud
Autor:
Isabell Schulze, Zoe Quandt, Alexander Gusev, Melinda C. Aldrich, Andrew J. Plodkowski, Mohsen Abu-Akeel, Jia Luo, Taha Merghoub, Victoria Martucci, Jacklynn V. Egger, Donglei Hu, Hira Rizvi, Matthew A. Gubens, Scott Huntsman, Megan H. Murray, Christine M. Lovly, Matthew D. Hellmann, Elad Ziv, Min Li, Stefan Groha, Eduardo Cardenas
Publikováno v:
Clin Cancer Res
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 27, iss 18
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 27, iss 18
Purpose: Genetic differences in immunity may contribute to toxicity and outcomes with immune checkpoint inhibitor (CPI) therapy, but these relationships are poorly understood. We examined the genetics of thyroid immune-related adverse events (irAE).
Autor:
Maria E. Arcila, Charles M. Rudin, Glenn Heller, Adam J. Schoenfeld, Gregory J. Riely, Marc Ladanyi, Jessica Flynn, Hira Rizvi, Mark G. Kris, Helena A. Yu, Noura J. Choudhury, Christina Falcon
Publikováno v:
Clin Cancer Res
Purpose: EGFR exon 20 insertions (ex20ins) are an uncommon genotype in non–small cell lung cancer (NSCLC) for which targeted therapies are under development. We sought to describe treatment outcomes and genomic and immunophenotypic characteristics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96ab74d61f0f759a9ab027ae10ff52f8
https://europepmc.org/articles/PMC8127357/
https://europepmc.org/articles/PMC8127357/
Autor:
Maria E. Arcila, Marc Ladanyi, Mark G. Kris, Piro Lito, Andrea Knezevic, Charles M. Rudin, Andrew J. Plodkowski, Gregory J. Riely, Kathryn C. Arbour, Matthew D. Hellmann, Hira Rizvi, Helena A. Yu, Glenn Heller
Publikováno v:
Clin Cancer Res
Purpose: KRAS mutations are identified in approximately 30% of patients with non–small cell lung cancer (NSCLC). Novel direct inhibitors of KRAS G12C have shown activity in early-phase clinical trials. We hypothesized that patients with KRAS G12C m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ef3e399cd666fae324945722c2d7124
https://europepmc.org/articles/PMC8771577/
https://europepmc.org/articles/PMC8771577/
Autor:
Michael A. Postow, Matthew D. Hellmann, Hira Rizvi, Jason Beattie, Mohit Chawla, Allison Betof Warner, Adam J. Schoenfeld, Martin H. Voss, Margaret K. Callahan, Jia Luo, I-Hsin Lin, Paige Fuentes, Neil J. Shah
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundPneumonitis related to immune checkpoint blockade is uncommon but can be severe, fatal or chronic. Steroids are first-line treatment, however, some patients are refractory or become resistant to steroids. Like many immune-related adverse ev
Autor:
Andrew J. Plodkowski, Jia Luo, Biagio Ricciuti, Joao Victor Machado Alessi, Zihan Wei, Matthew D. Hellmann, Hira Rizvi, Mizuki Nishino, Mehmet Altan, Peter Sawan, Brett W. Carter, John V. Heymach, Mark M. Awad, Fangxin Hong, Elizabeth Jimenez-Aguilar
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundPatients with non–small cell lung cancer (NSCLC) and a poor Eastern Cooperative Oncology Group Performance Status (ECOG PS) have been excluded from phase III immunotherapy clinical trials. We sought to evaluate clinical outcomes to first-
Autor:
Adam J, Schoenfeld, Chai, Bandlamudi, Jessica A, Lavery, Joseph, Montecalvo, Azadeh, Namakydoust, Hira, Rizvi, Jacklynn, Egger, Carla P, Concepcion, Sonal, Paul, Maria E, Arcila, Yahya, Daneshbod, Jason, Chang, Jennifer L, Sauter, Amanda, Beras, Marc, Ladanyi, Tyler, Jacks, Charles M, Rudin, Barry S, Taylor, Mark T A, Donoghue, Glenn, Heller, Matthew D, Hellmann, Natasha, Rekhtman, Gregory J, Riely
Publikováno v:
Clin Cancer Res
PURPOSE: SMARCA4 mutations are among the most common recurrent alterations in NSCLC, but the relationship to other genomic abnormalities and clinical impact has not been established. EXPERIMENTAL DESIGN: To characterize SMARCA4 alterations in NSCLC,
Autor:
Jesse M. Zaretsky, Jacklin Gukasyan, John Madrigal, James M. Carroll, David Elashoff, Steven M. Dubinett, Jonathan W. Goldman, Daniel K. Wells, I. Peter Shintaku, Edward B. Garon, Antoni Ribas, Hira Rizvi, Benjamin P Jones, Dennis J. Slamon, Siwen Hu-Lieskovan, Aaron Lisberg, Matthew D. Hellmann, Tristan Grogan, Amy L. Cummings
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 25(16)
Purpose: Several biomarkers have been individually associated with response to PD-1 blockade, including PD-L1 and tumor mutational burden (TMB) in non–small cell lung cancer (NSCLC), and CD8 cells in melanoma. We sought to examine the relationship
Autor:
Ralf Gutzmer, Claus Garbe, Hira Rizvi, Alisa Y. Kane, Luke Ardolino, Paolo A. Ascierto, Ogochukwu M. Ezeoke, Victoria Atkinson, Alexander M. Menzies, Jennifer L. McQuade, Matthew D. Hellmann, Lisa Zimmer, Simone M. Goldinger, Georgina V. Long, Lavinia Spain, Justine V. Cohen, Martin Tio, Michael Millward, Douglas B. Johnson, John J. Park, Rajat Rai, Desmond Yip, Chloe Khoo, Samra Turajlic, Anthony M. Joshua
Publikováno v:
Eur J Cancer
Background Anti-programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) immunotherapy is now routinely used to treat several cancers. Clinical trials have excluded several populations, including patients with solid organ transplant, HI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88ca2382f6383ee824a1796afdc859fe
https://europepmc.org/articles/PMC10176037/
https://europepmc.org/articles/PMC10176037/
Autor:
Hira Rizvi, Andrea Knezevic, Piro Lito, Mark G. Kris, Maria E. Arcila, Darragh Halpenny, Andrew J. Plodkowski, Charles M. Rudin, Kathryn C. Arbour, Matthew D. Hellmann, Helena Alexandra Yu, Gregory J. Riely, Glenn Heller, Marc Ladanyi
Publikováno v:
Journal of Clinical Oncology. 38:9596-9596
9596 Background: KRAS mutations are identified in approximately 30% of NSCLC. There are no FDA approved targeted therapies for patients with KRAS-mutant non-small cell lung cancer (NSCLC) but novel direct inhibitors of KRAS G12C have shown some activ